JJ, the last enrollees just finished their second year in the September/October time frame. Might not have time to get the 2 year data together in time, but 18/21 month data should be ready for disclosure.
I believe many here are misinterpreting this “104 week” extension. It’s a completely new trial that starts at “week 0”.
Estimated Enrollment: 32
Study Start Date: March 2016
Estimated Study Completion Date: November 2018 https://clinicaltrials.gov/ct2/show/NCT02756858?term=Anavex&rank=2
“NEW YORK, NY – March 10, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks,
providing an opportunity to gather extended safety and efficacy data. “ http://www.anavex.com/anavex-announces-two-year-clinical-extension-study-of-anavex-2-73-and-presents-phase-2a-dose-response-analysis-at-aat-conference/
The first patients won’t complete two years until March 2018 and the last patients won’t complete 104 weeks until Nov 2018